$4.30
2.27% today
Nasdaq, Nov 03, 04:37 pm CET
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$4.40
+0.31 7.58% 1M
-6.05 57.89% 6M
-9.27 67.81% YTD
+1.37 45.21% 1Y
-2.75 38.46% 3Y
-223.60 98.07% 5Y
-460.60 99.05% 10Y
-460.60 99.05% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.04 0.90%
ISIN
US30205M1018
Symbol
XCUR
Industry

Key metrics

Basic
Market capitalization
$31.6m
Enterprise Value
$23.7m
Net debt
positive
Cash
$7.9m
Shares outstanding
6.3m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
45.0%
Return on Equity
-143.3%
ROCE
-58.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-8.2m | -
EBIT
$-8.4m | -
Net Income
$-7.9m | -
Free Cash Flow
$-5.5m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-22.2% | -
EBIT
-21.3% | -
Net Income
3.5% | -
Free Cash Flow
-43.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.2
FCF per Share
$-0.9
Short interest
1.0%
Employees
7
Rev per Employee
$70.0k
Show more

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

Hold
50%
Sell
50%

Financial data from Exicure Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.61 6.61
2% 2%
-
- Research and Development Expense 1.74 1.74
-
-
-8.21 -8.21
22% 22%
-
- Depreciation and Amortization 0.15 0.15
12% 12%
-
EBIT (Operating Income) EBIT -8.35 -8.35
21% 21%
-
Net Profit -7.88 -7.88
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Neutral
GlobeNewsWire
about 2 hours ago
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meetin...
Neutral
Business Wire
12 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you currently own Exicure stock and acquired shares on or before January 7, 2021, you may be able to seek corporate governance reforms, the return of funds back to the company, a cour...
Neutral
GlobeNewsWire
28 days ago
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise REDWOOD CITY, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today sh...
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Andy Yoo
Employees 7
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today